Robotic Choledochal Cyst Excision With Intracorporeal Roux‐en‐Y Hepaticojejunostomy in Adolescent and Adult Patients: Clinical and Quality‐of‐Life Outcomes

INTRODUCTION: This study evaluates clinical and health-related-quality-of-life (HRQOL) outcomes following robotic choledochal cyst (CDC) excision with intracorporeal Roux-en-Y hepaticojejunostomy. METHOD: Prospectively maintained data from 17 consecutive patients undergoing robotic CDC excision with the da Vinci Xi system (January 2017-October 2024) were retrospectively analysed. RESULTS: Fifteen patients were female; median age was 22 year. Cyst types included Ia(6), Ic(3), IVa(5), II(1), and VIb(2). Median operative time was 360 min, blood loss 50 mL, and hospital stay 4 days. Postoperative complications occurred in three patients, including one clinically-relevant grade-B postoperative-pancreatic-fistula requiring image-guided drainage (Clavien-Dindo IIIa), one biochemical POPF, and one episode of mild acute-pancreatitis. At a median follow-up of 36.5-month (IQR 35-43), no anastomotic strictures, malignancy, or biliary complications were noted. At 12-month, the median Gastrointestinal-Quality-of-Life-Index (GIQLI) score was 135 (IQR 133.5-136). CONCLUSION: Robotic CDC excision with intracorporeal reconstruction appears feasible and safe in selected patients, with favourable perioperative and functional outcomes.